提炼
我们感谢L. Zhang和同事对我们的手稿的书信。在与全身性硬化症(SSC-ILD)相关的间质肺疾病中,缺乏有效的预后生物标志物会阻碍个性化的患者管理。我们的研究将放射素学引入了一种新型的非侵入性工具,可从现有的标准高分辨率计算机断层扫描图像中获取表型,预后和分子信息,具有支持SSC-ILD临床决策的巨大潜力[1]。
摘要
我们讨论了放射素学作为一种新型的非侵入性工具的利弊,以获取来自ILD患者的现有标准高分辨率高分辨率计算机断层扫描的表型,预后和分子信息。https://bit.ly/36vyyl2
Footnotes
Conflict of interest: J. Schniering, M. Maciukiewicz and S. Tanadini-Lang have no competing interests to declare. B. Maurer has consultancies with Novartis, Boehringer Ingelheim and Janssen-Cilag, had grant/research support from AbbVie, Protagen and Novartis Biomedical Research, received speaker fees from Boehringer Ingelheim and Novartis, as well as congress support from Medtalk, Pfizer, Roche, Actelion, mepha and MSD. In addition, B. Maurer has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143).
- ReceivedFebruary 9, 2022.
- 公认March 13, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact权限{at} ersnet.org